BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T130000
DTEND;TZID=America/New_York:20251112T140000
DTSTAMP:20260423T051541
CREATED:20251029T145821Z
LAST-MODIFIED:20251029T150136Z
UID:71751-1762952400-1762956000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - VONVENDI® [von Willebrand Factor (Recombinant)] [Now] Approved for Adults and Pediatric Patients
DESCRIPTION:Date: Wednesday\, November 12th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nVONVENDI® [von Willebrand Factor (Recombinant)] [Now] Approved for Adults and Pediatric Patients. \nOBJECTIVE: \n\nUnderstand the underlying mechanism of VWD and the role of VWF.\nReview unmet needs in the treatment of VWD.\nIdentify the unique characteristics of VONVENDI as the first and only recombinant treatment for patients with VWD.\nReview hypothetical patient cases and clinical data for on-demand\, prophylactic\, and surgical control of bleeds with VONVENDI.\n\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nDr. Jonathan Roberts \nDr. Roberts graduated from the Southern Illinois School of Medicine in 2008 and completed his internship and residency in Pediatrics at the University of Illinois College of Medicine at Peoria at OSF HealthCare Children’s Hospital of Illinois in 2011. After finishing his residency\, Dr. Roberts completed fellowship in Pediatric Hematology/Oncology/Blood & Marrow Transplantation at the Medical College of Wisconsin/Children’s Hospital of Wisconsin in 2014 and worked as a post-doctoral fellow under Dr. Robert Montgomery and Dr. Joan Cox Gill at the Blood Center of Wisconsin Blood Research Institute. In addition to being the Associate Medical Director/Associate Research Director of BCDI\, Dr. Roberts is also an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria\, IL. \nDr. Roberts’ research areas of interest are in advancing novel laboratory assay development to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia\, VWD\, and other rare bleeding and classical hematologic disorders. He has received numerous young investigator research awards\, has over 100 peer-reviewed research publications and abstracts including lead/senior author publications in Blood\, the Journal of Thrombosis and Haemostasis\, and the New England Journal of Medicine; and has had grant funding from the National Bleeding Disorders Foundation\, World Federation of Hemophilia and National Institutes of Health among others. \nDr. Roberts has a personal passion for the bleeding disorders community as he is also an individual with severe hemophilia A. \nDisclosures: \nNovo Nordisk\, Octapharma\, Sanofi\, Takeda\, Genentech\, Pfizer\, F. Hoffmann-La Roche AG
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-vonvendi-von-willebrand-factor-recombinant-now-approved-for-adults-and-pediatric-patients/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR